AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$AUPH

Robertson Stephen P. sold $356K of AUPH

Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.

Original reporting
SEC EDGAR · Robertson Stephen P.
Published Aug 26, 2026, 1:29 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AUPH
Bearish
medium confidence
Mentioned
$AUPH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBearishLow
01

Why it matters

The transaction is a primary disclosure but modest in scale, offering limited trading insight.

02

Market read

Small insider sale with limited price impact.

03

What to watch

No other material news coincides with the filing.

Relevance 4/10Novelty 4/10Timing: post-market 2026-08-21

Background

Form 4 filing by Aurinia's Chief Legal Officer discloses a direct sale of shares.

Company-level read

Ticker impact

$AUPHBearishMedium confidence
Context

Chief Legal Officer sold 20,975 shares for $355,946 on 2026-08-21, reducing his stake.

Expected impact

Potential short-term pressure on AUPH price.

Evidence & confidence

Sale size is modest but insider status adds weight.

Market effects

Sector

Minimal impact on biotech sector.

Regional

None.

Global

Low.

Counterpoint

What could challenge this read

Sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Aurinia Pharmaceuticals Inc.

    Biotech firm listed on NASDAQ (AUPH).

  • Executive
    Robertson Stephen P.

    Chief Legal Officer of Aurinia.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min
AUG 19
$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

leaderpost.com2 min